Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Non-cash Items (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Non-cash Items for 2 consecutive years, with $27000.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 90.43% to $27000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27000.0 through Dec 2025, down 90.43% year-over-year, with the annual reading at $27000.0 for FY2025, 90.43% down from the prior year.
  • Non-cash Items hit $27000.0 in Q4 2025 for Xilio Therapeutics, down from $6.5 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $6.5 million in Q3 2025 to a low of $27000.0 in Q4 2025.